Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer
Clinical trial NCT00463788 · COMPLETED
Trial details
- NCT number
- NCT00463788
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-06-01
- Primary completion
- 2009-07-01
- Enrollment
- 181
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.